-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
WM is a lymphocyte tumor characterized by lymphatic plasma cells soaking the bone marrow and increasing the number of cloned immunoglobulin M (IgM) in the blood list.
is a rare disease that accounts for less than 2% of non-Hodgkin's lymphoma patients in the United States.
The objective remission rate (ORR) of WM's treatment options recommended in the current guidelines can reach 80%, but the deeper remission rate above good partial remission (VGPR) is very low (about 20% or less), and more patients will eventually relapse or progress.
, the middle age of WM is around 70 years old, and the patient's physical condition is often insatiable with intense treatment.
the improvement of WM therapeutic effect is an urgent clinical problem to be solved.
. Datamonitor, Market Spotlight: WM published on April 17, 2020. Note: The original text is reduced.